
Defeating Food Allergies | Kari Nadeau

Defeating Food Allergies | Kari Nadeau
April 9, 2019
•
1hr 47m
•
Episode Ranking: 9/100
TOPICS: Evolution
Episode Description
Food Allergies & Scientific Breakthroughs: Scientists work to unravel the growing mystery of food allergies. Kari Nadeau and her team explore potential cures. The episode reveals the increasing prevalence and severity of allergies.
Ideabrix Summary
The 'Defeating Food Allergies | Kari Nadeau' episode of 'The After On Podcast' features a comprehensive discussion with Stanford immunologist Kari Nadeau, an expert in the field of food allergies. Host Rob Reed introduces the episode by highlighting the alarming increase in food allergies over recent decades, an issue affecting millions worldwide. Nadeau, who runs the Sean Parker Center for Allergy and Asthma Research at Stanford, delves into the mysterious surge in food allergies, exploring potential causes and the complex biology of the immune system.
Nadeau shares her insights on the rise of food allergies, noting that the prevalence has skyrocketed from a mere 0.1% of the population in the 1940s to about 8% of children under the age of 21 by 2011. She discusses the 'hygiene hypothesis,' environmental factors, and genetic predispositions as potential contributors to this epidemic. The conversation also touches on the evolution of food allergies from a predominantly childhood condition to one that increasingly affects adults, with many adults developing allergies to foods they previously consumed without issue.
The episode delves into the biology of food allergies, explaining the role of immunoglobulin E (IgE) antibodies in allergic reactions. Nadeau describes how IgE mistakenly identifies harmless food proteins as threats, leading to the release of histamines and other chemicals that cause allergic symptoms. She also emphasizes the importance of epinephrine in treating severe allergic reactions and the need for widespread availability of epinephrine auto-injectors.
Nadeau and Reed discuss oral immunotherapy (OIT), a treatment approach that gradually exposes patients to increasing amounts of an allergen to build tolerance. Nadeau shares her pioneering work in using OIT in conjunction with the drug omalizumab (Xolair) to treat multiple food allergies simultaneously, a method that has shown promising results. She also highlights the potential of biomarkers and emerging therapies, including vaccines, to improve the diagnosis and treatment of food allergies.
Throughout the episode, Nadeau stresses the need for more research, better diagnostics, and therapies that are safe, effective, and accessible to all. She reflects on her personal experiences with allergies and her motivation to advance the field, driven by a desire to prevent others from suffering and to find permanent solutions to this growing health concern.
Nadeau shares her insights on the rise of food allergies, noting that the prevalence has skyrocketed from a mere 0.1% of the population in the 1940s to about 8% of children under the age of 21 by 2011. She discusses the 'hygiene hypothesis,' environmental factors, and genetic predispositions as potential contributors to this epidemic. The conversation also touches on the evolution of food allergies from a predominantly childhood condition to one that increasingly affects adults, with many adults developing allergies to foods they previously consumed without issue.
The episode delves into the biology of food allergies, explaining the role of immunoglobulin E (IgE) antibodies in allergic reactions. Nadeau describes how IgE mistakenly identifies harmless food proteins as threats, leading to the release of histamines and other chemicals that cause allergic symptoms. She also emphasizes the importance of epinephrine in treating severe allergic reactions and the need for widespread availability of epinephrine auto-injectors.
Nadeau and Reed discuss oral immunotherapy (OIT), a treatment approach that gradually exposes patients to increasing amounts of an allergen to build tolerance. Nadeau shares her pioneering work in using OIT in conjunction with the drug omalizumab (Xolair) to treat multiple food allergies simultaneously, a method that has shown promising results. She also highlights the potential of biomarkers and emerging therapies, including vaccines, to improve the diagnosis and treatment of food allergies.
Throughout the episode, Nadeau stresses the need for more research, better diagnostics, and therapies that are safe, effective, and accessible to all. She reflects on her personal experiences with allergies and her motivation to advance the field, driven by a desire to prevent others from suffering and to find permanent solutions to this growing health concern.
Subscribe to our Premium Plan to learn more.
Discover more about this episode
Summary and conclusion
Key takeaways
Quotes
Vocabulary
Mentioned media
Mentioned people